Jane Street’s ALX Oncology ALXO Stock Holding History

Jane Street’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-20,500	Closed	-$23.2K	–	11470
2025 Q4	$23.2K	Buy	+20,500	New	+$31K	﹤0.01%	10696

Other funds holding ALXO

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Jane Street's ALXO Position: Q2 2026 in Review

Jane Street sold out of ALX Oncology (ALXO) in Q2 2026, closing a stake of 95,101 shares — an estimated $191K sold.

Jane Street first reported a position in ALXO in Q3 2022 and held it in 11 quarters. The position peaked at $660K in Q1 2024. 94 funds tracked by Wall St. Rank hold ALXO as of Q2 2026.

Jane Street reported no remaining ALX Oncology position as of Q2 2026 after selling out during the quarter.
Jane Street sold 95,101 ALX Oncology shares in Q2 2026, an estimated $191K.
Jane Street first reported a position in ALX Oncology in Q3 2022 and held it in 11 quarters.
Jane Street's ALX Oncology position peaked at $660K in Q1 2024.
94 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.